Having lived and worked in China for five years earlier in my career, I was both pleased, and curious, to return after a long absence. This visit brought me to Shanghai to host a discussion at the 14th Asia Pharmaceutical R&D Leadership Summit (APRL).
When I first began working in China, the pharmaceutical industry’s key advantages were its speed and capacity to scale. By 2019, it seemed as though most local companies were focused on “fast‑follow” or “me‑too” drug development, mostly achieved through in‑licensing agreements. Clinical trials for multinational firms were used primarily to accelerate patient enrollment, while regulatory reforms progressed unevenly across the sector.
Now, in early 2026, change is striking. The most significant differentiators include:
- Quality and differentiation are replacing fast‑follow approaches
- Assets are designed from day one for global development and approval
- Clinical trials increasingly include first‑in‑human, proof‑of‑concept, and registrational studies
- Regulatory processes are more predictable and aligned with global standards
- The ecosystem is more focused, selective, and resilient
- China is exporting more truly innovative assets
At Lumanity, our commitment to Engineering Breakthrough Value positions us to help in the evolution that is underway in China. My experience in both China’s biotech industry and global R&D leadership gives us the technical, cultural, and strategic insight to support China‑based innovators, and help them succeed responsibly on the world stage.
Interested in more insight on how China’s Biopharma industry is transforming?
Get in touch at contact@lumanity.com.
